M. Isabel Chiu

1.6k total citations
22 papers, 1.3k citations indexed

About

M. Isabel Chiu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, M. Isabel Chiu has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in M. Isabel Chiu's work include Cancer, Hypoxia, and Metabolism (4 papers), GDF15 and Related Biomarkers (4 papers) and Cancer-related Molecular Pathways (4 papers). M. Isabel Chiu is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), GDF15 and Related Biomarkers (4 papers) and Cancer-related Molecular Pathways (4 papers). M. Isabel Chiu collaborates with scholars based in United States and Canada. M. Isabel Chiu's co-authors include Howard R. Katz, Vivian Berlin, Jeremy Nathans, Lorena Lerner, Mark Rolfe, Nianjun Tao, Michele Pagano, Bin Feng, Richard Nicoletti and Brian Krieger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Nature Biotechnology.

In The Last Decade

M. Isabel Chiu

22 papers receiving 1.2k citations

Peers

M. Isabel Chiu
Shaun S. Abeysinghe United Kingdom
Selen C. Muratoglu United States
Victoria J. South United States
Jan Saras Sweden
Larbi Amazit France
Felicity Newell Australia
Takeshi Yamada Japan
Alec W. Gross United States
Saya Ito Japan
Rachael Daniel United States
Shaun S. Abeysinghe United Kingdom
M. Isabel Chiu
Citations per year, relative to M. Isabel Chiu M. Isabel Chiu (= 1×) peers Shaun S. Abeysinghe

Countries citing papers authored by M. Isabel Chiu

Since Specialization
Citations

This map shows the geographic impact of M. Isabel Chiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Isabel Chiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Isabel Chiu more than expected).

Fields of papers citing papers by M. Isabel Chiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Isabel Chiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Isabel Chiu. The network helps show where M. Isabel Chiu may publish in the future.

Co-authorship network of co-authors of M. Isabel Chiu

This figure shows the co-authorship network connecting the top 25 collaborators of M. Isabel Chiu. A scholar is included among the top collaborators of M. Isabel Chiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Isabel Chiu. M. Isabel Chiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suiter, Chase C., Diego Calderon, David Lee, et al.. (2025). Combinatorial mapping of E3 ubiquitin ligases to their target substrates. Molecular Cell. 85(4). 829–842.e6. 3 indexed citations
2.
Scheuplein, Felix, Sheila Ranganath, Thomas J. McQuade, et al.. (2016). Abstract B30: Discovery and functional characterization of novel anti-PD-1 antibodies using ex vivo cell-based assays, single-cell immunoprofiling, and in vivo studies in humanized mice. Cancer Research. 76(15_Supplement). B30–B30. 3 indexed citations
3.
Lerner, Lorena, Teresa G. Hayes, Nianjun Tao, et al.. (2015). Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. Journal of Cachexia Sarcopenia and Muscle. 6(4). 317–324. 152 indexed citations
4.
Zhou, Yinghui, William M. Rideout, Sireesha Yalavarthi, et al.. (2014). Spontaneous Genomic Alterations in a Chimeric Model of Colorectal Cancer Enable Metastasis and Guide Effective Combinatorial Therapy. PLoS ONE. 9(8). e105886–e105886. 13 indexed citations
5.
Viganò, Antonio, Lorena Lerner, Nianjun Tao, et al.. (2013). Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia.. Cancer Research. 73(8_Supplement). 4650–4650. 3 indexed citations
6.
Hayes, Teresa G., Nianjun Tao, Brian Krieger, et al.. (2013). Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients.. Cancer Research. 73(8_Supplement). 3504–3504. 2 indexed citations
7.
8.
Buck, Elizabeth, Prafulla C. Gokhale, Susan Koujak, et al.. (2010). Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer. Molecular Cancer Therapeutics. 9(10). 2652–2664. 183 indexed citations
9.
Feng, Bo, Xiaoxu Sun, William M. Rideout, et al.. (2010). Correlation of a tivozanib response biomarker identified in a preclinical model with clinical activity in a phase II study in renal cell carcinoma (RCC).. Journal of Clinical Oncology. 28(15_suppl). e13564–e13564. 2 indexed citations
10.
Watters, James, Chun Cheng, Pradip K. Majumder, et al.. (2009). De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model. Cancer Research. 69(23). 8949–8957. 31 indexed citations
11.
Zhou, Yinghui, William M. Rideout, Tong Zi, et al.. (2009). Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas. Nature Biotechnology. 28(1). 71–78. 59 indexed citations
12.
Zi, Tong, William M. Rideout, M. Isabel Chiu, et al.. (2009). Abstract A22: Response to the triple VEGFR inhibitor tivozanib (AV-951) in KRAS and EGFR driven lung tumors developed in chimeric mouse models. Molecular Cancer Therapeutics. 8(12_Supplement). A22–A22. 1 indexed citations
13.
Liu, Qing, Nianjun Tao, Lu Huang, et al.. (2009). Abstract A233: Generation of in vitro and in vivo tumor models driven by insulin-like growth factor receptor (IGF1R) and their use in the development of OSI-906, a selective IGF1R inhibitor. Molecular Cancer Therapeutics. 8(12_Supplement). A233–A233. 1 indexed citations
14.
Farlow, Samuel J., Tong Zi, Xiao‐Jian Sun, et al.. (2009). Abstract A12: Variation in response to triple VEGFR inhibitor tivozanib in mouse models of hepatocellular carcinoma. Molecular Cancer Therapeutics. 8(12_Supplement). A12–A12. 4 indexed citations
15.
16.
Rolfe, Mark, M. Isabel Chiu, & Michele Pagano. (1997). The ubiquitin-mediated proteolytic pathway as a therapeutic area. Journal of Molecular Medicine. 75(1). 5–17. 91 indexed citations
17.
Chiu, M. Isabel, Donald J. Zack, Yanshu Wang, & Jeremy Nathans. (1994). Murine and Bovine Blue Cone Pigment Genes: Cloning and Characterization of Two New Members of the S Family of Visual Pigments. Genomics. 21(2). 440–443. 55 indexed citations
18.
Chiu, M. Isabel & Jeremy Nathans. (1994). A sequence upstream of the mouse blue visual pigment gene directs blue cone-specific transgene expression in mouse retinas. Visual Neuroscience. 11(4). 773–780. 55 indexed citations
19.
Chiu, M. Isabel, Howard R. Katz, & Vivian Berlin. (1994). RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.. Proceedings of the National Academy of Sciences. 91(26). 12574–12578. 375 indexed citations
20.
Chiu, M. Isabel, Thomas L. Mason, & Gerald R. Fink. (1992). HTS1 encodes both the cytoplasmic and mitochondrial histidyl-tRNA synthetase of Saccharomyces cerevisiae: mutations alter the specificity of compartmentation.. Genetics. 132(4). 987–1001. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shaun S. Abeysinghe Breakdown of academic impact, for papers by Selen C. Muratoglu Breakdown of academic impact, for papers by Victoria J. South Breakdown of academic impact, for papers by Jan Saras Breakdown of academic impact, for papers by Larbi Amazit Breakdown of academic impact, for papers by Felicity Newell Breakdown of academic impact, for papers by Takeshi Yamada Breakdown of academic impact, for papers by Alec W. Gross Breakdown of academic impact, for papers by Saya Ito Breakdown of academic impact, for papers by Rachael Daniel
Rankless by CCL
2026